Rochester represents at Nobel Prize ceremony

The groundbreaking work of three scholars with ties to the University of Rochester took center stage when pioneering laser scientist Donna Strickland ’89 (PhD) and her Rochester advisor Gerard Mourou formally received the Nobel Prize in Physics, and Paul Romer, whose early career tenure-track appointment was in Rochester’s Department of Economics, received the Nobel Prize in Economic Sciences.

Strickland, who is now an associate professor of physics and astronomy at the University of Waterloo in Ontario, Canada, and Mourou, now a professor at the École Polytechnique in France, are being recognized for their Rochester work to develop “chirped-pulse amplification,” a technology that harnesses the power of lasers as precision tools and helped pave the way for laser-eye surgery, the machining of key parts for cell phones and other devices, tools for cancer treatment, and other clinical and commercial applications. The technology was the basis for Strickland’s 1988 doctoral dissertation at Rochester, where she was a graduate student working with Morou at the University’s Laboratory for Laser Energetics. They both receive a share of the Nobel Prize in Physics.

Romer, who was an assistant professor in the Department of Economics from 1982 to 1988 shortly after receiving his PhD from the University of Chicago, will be awarded the Nobel Prize for his work to assess the interaction of technology, productivity, and economic growth. He shares the prize with economist William Nordhaus of Yale University.

Watch the Nobel Prize ceremony online and read messages of congratulations from members of the University of Rochester community.

From left, Paul Romer, whose early career tenure-track appointment was in Rochester’s Department of Economics, received the Nobel Prize in Economic Sciences. Pioneering laser scientist Donna Strickland ’89 (PhD) and her Rochester advisor Gerard Mourou formally received the Nobel Prize in Physics. (Getty Images photos)

 

 

Koning Breast CT Nominated for Best Medical Technology

Koning Corporation’s breast computed tomography (KCBT 1000) system was nominated for Best Medical Technology at the 12th annual Prix Galien awards. The Prix Galien awards recognize outstanding achievements in improving the human condition through the development of innovative therapies. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

Koning Corporation’s breast CT device, based on the patented research of Dr. Ruola Ning, is the only FDA-approved breast CT imaging system on the market. A unique modality, the KBCT provides 3D images of the breast – without compression and with high dose efficiency within the 10-second scan. This technology allows for precise detection, assessment, and quantification of abnormalities, especially in women with dense breast tissue. With the potential to dramatically improve the way clinicians visualize and evaluate breast tissue, Koning hopes to be able to improve survival rates and outcomes for millions of patients.

The KCBT’s nomination for Best Medical Technology represents a significant confirmation of the technology’s value. The Koning Corporation was honored to be recognized by the Prix Galien.

(L-R) Global Chief Operating Officer, Lutao Ning, Global Chairman and CEO, Dr. Ruola Ning, North American President, David Georges, and Global Chief Financial Officer, Matt Stack, attend the 12th annual Prix Galien awards on October 24, 2018.

 

Latest Drug Development Pilot Awards Announced

Five projects received Drug Development Pilot Awards in the latest round:

Development of UR214-7 and UR214-9 for cancer treatments
Kyu Kwang Kim, Department of Obstetrics and Gynecology

Small Molecule Modulators of U2AF-Dependent Splicing in Myelodysplastic Syndromes
Clara L. Kielkopf, Department of Biochemistry and Biophysics

Innate Immunity guided screening for apicomplexan profilins
Felix Yarovinsky, Department of Microbiology and Immunology

Creation and development of fully-transmembrane receptor effectors
Omar Bakht and Omar Aljitawi, Department of Medicine, Hematology / Oncology

A new alarmin S100A11 in host defense and inflammation
Felix Yarovinsky, Department of Microbiology and Immunology

The Drug Development Pilot Award Program (DDPA) supports projects in drug development research that result in technology development, extramural funding, and commercialization. This program is restricted to SMD faculty and awards funds up to $10,000 or $50,000, depending upon the award type.

To learn more about the DDPA, visit: http://www.rochester.edu/ventures/for-ur-innovators/resources-innovators/drug-development-pilot-award/

Latest Technology Development Fund Awards Announced

The Technology Development Fund (TDF) made four awards in the latest round. Awards ranged from $50,000 – $100,000 for projects of one-year in length.

Interested to learn more about the projects funded in this round? Contact us.

Fiber Array to Silicon Photonic Chip Optical Packaging
Jaime Cardenas, Institute of Optics

Pre-clinical development of a human monoclonal antibody cocktail (URnFluhmAb) for the universal prevention and treatment of influenza infection
James Kobie, Department of Medicine and Luis Martinez-Sobrido, Department of Microbiology & Immunology

Development of URML-3881, a small molecule MEK inhibitor for the treatment of cancers with high MAP kinase pathway activity
Rachael Turner, Department of Hematology/Oncology

Inscriptr Gene Therapy
Douglas Anderson, Department of Medicine

The TDF solicits proposals twice a year. Qualified applicants include University of Rochester faculty, students, or staff who have filed an invention disclosure with UR Ventures. Eligible projects propose the development of a technology to a more commercial endpoint. Awards range from $40,000 to $100,000.

To learn more about the TDF, visit: http://www.rochester.edu/tdf/